Sipuleucel-T is a type of cancer immunotherapy. It is a personalized treatment used to treat men with advanced prostate cancer. It works by stimulating the patient’s own immune system to recognize and attack cancer cells. It contains antigen-presenting cells (APCs) that have been modified to carry a specific protein called prostate-specific antigen (PSA). The modified APCs can then recognize and target prostate cancer cells. Sipuleucel-T is administered through an intravenous infusion every two to four weeks over the course of several months. It is typically used in combination with other treatments, including hormone therapy and chemotherapy.
Sipuleucel-T, also sold under the brand name Provenge, is a type of immunotherapy treatment for a specific type of prostate cancer [1]. Here's a breakdown of its key features:
- Cancer it targets: Metastatic castration-resistant prostate cancer (mCRPC). This is an advanced form where the cancer has spread to other parts of the body and hormone therapy is no longer effective [1, 2].
- How it works: Sipuleucel-T is a personalized cellular immunotherapy. This means it uses a patient's own immune cells to target the cancer [1]. Here's the process:
- Blood is drawn from the patient [2].
- Immune cells are extracted and stimulated in a lab to target prostate cancer cells [2].
- The modified cells are then infused back into the patient's body [2].
- The stimulated cells are supposed to help the immune system recognize and attack prostate cancer cells [2].
- Treatment course: Sipuleucel-T is typically given as a slow intravenous (in the vein) infusion every two weeks for a total of three doses [2].
Important things to consider:
- Sipuleucel-T may not be suitable for everyone with mCRPC. It's important to discuss candidacy with a healthcare professional [1].
- The main benefit of Sipuleucel-T is believed to be improved survival rates, although the increase may be modest (around 4 months) [2].
- Sipuleucel-T can cause side effects, such as chills, fatigue, fever, and back pain [2].